No information is available on the clinical use of sacituzumab govitecan during breastfeeding. Because sacituzumab is a large protein molecule, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Govitecan is a small-molecule anticancer drug that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that women not breastfeed during treatment and for at least 1 month after the final dose.
关于在母乳喂养期间使用戈沙妥珠单抗的临床信息尚无可用资料。由于戈沙妥珠单抗是一种大分子蛋白质，乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收量可能极少。[2]伊立替康是一种小分子抗癌药物，可能进入乳汁并被婴儿吸收。由于母乳喂养的婴儿可能发生严重不良反应，制造商建议女性在治疗期间及最后一剂后至少1个月内不要母乳喂养。
Zotero 插件